PCSK9 and hyperlipidemia: Moreover, a previous clinical study reported that proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors, primary indicated for the treatment of hyperlipidemia, also reduce the risk of AAA [31].